Literature DB >> 28460355

Development of combretastatins as potent tubulin polymerization inhibitors.

Syed Nasir Abbas Bukhari1, Gajjela Bharath Kumar2, Hrishikesh Mohan Revankar2, Hua-Li Qin3.   

Abstract

The combretastatins are isolated from South African tree combretum caffrum kuntze. The lead compound combretastatin A-4 has displayed remarkable cytotoxic effect in a wide variety of preclinical tumor models and inhibits tubulin polymerization by interacting at colchicine binding site of microtubule. However, the structural simplicity of C A-4 is favorable for synthesis of various derivatives projected to induce rapid and selective vascular shutdown in tumors. Majority of the molecules have shown excellent antiproliferative activity and are able to inhibit tubulin polymerization as well as possible mechanisms of action have been investigated. In this review article, the synthesis and structure-activity relationships of C A-4 and immense number of its synthetic derivatives with various modifications on the A, B-rings, bridge carbons and their anti mitotic activities are discussed.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticancer; Antiproliferative; Combretastatin A-4; Isolation; Natural products

Mesh:

Substances:

Year:  2017        PMID: 28460355     DOI: 10.1016/j.bioorg.2017.04.007

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  13 in total

1.  Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues.

Authors:  Casey J Maguire; Graham J Carlson; Jacob W Ford; Tracy E Strecker; Ernest Hamel; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2019-06-04       Impact factor: 3.597

2.  Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.

Authors:  Casey J Maguire; Zhi Chen; Vani P Mocharla; Madhavi Sriram; Tracy E Strecker; Ernest Hamel; Heling Zhou; Ramona Lopez; Yifan Wang; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2018-08-24       Impact factor: 3.597

Review 3.  Novel molecules as the emerging trends in cancer treatment: an update.

Authors:  Priyanka Sekar; Raashmi Ravitchandirane; Sofia Khanam; Nethaji Muniraj; Ananda Vayaravel Cassinadane
Journal:  Med Oncol       Date:  2022-01-04       Impact factor: 3.064

Review 4.  Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.

Authors:  Jiaxing Wang; Duane D Miller; Wei Li
Journal:  Drug Discov Today       Date:  2021-12-08       Impact factor: 7.851

Review 5.  Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.

Authors:  Li Liu; Devin O'Kelly; Regan Schuetze; Graham Carlson; Heling Zhou; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

Review 6.  More Than Resveratrol: New Insights into Stilbene-Based Compounds.

Authors:  Paulina Pecyna; Joanna Wargula; Marek Murias; Malgorzata Kucinska
Journal:  Biomolecules       Date:  2020-07-27

7.  Design, synthesis, and biological evaluation of novel 5,6,7-trimethoxy quinolines as potential anticancer agents and tubulin polymerization inhibitors.

Authors:  Salimeh Mirzaei; Farhad Eisvand; Farzin Hadizadeh; Fatemeh Mosaffa; Razieh Ghodsi
Journal:  Iran J Basic Med Sci       Date:  2020-12       Impact factor: 2.699

Review 8.  Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.

Authors:  Gökçe Şeker Karatoprak; Esra Küpeli Akkol; Yasin Genç; Hilal Bardakci; Çiğdem Yücel; Eduardo Sobarzo-Sánchez
Journal:  Molecules       Date:  2020-05-31       Impact factor: 4.411

9.  Antiproliferative benzothiazoles incorporating a trimethoxyphenyl scaffold as novel colchicine site tubulin polymerisation inhibitors.

Authors:  Dong-Jun Fu; Si-Meng Liu; Fu-Hao Li; Jia-Jia Yang; Jun Li
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

10.  A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Authors:  Fatih M Uckun; Christopher R Cogle; Tara L Lin; Sanjive Qazi; Vuong N Trieu; Gary Schiller; Justin M Watts
Journal:  Cancers (Basel)       Date:  2019-12-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.